Public Health Commons^™

Covid-19 And Vaccination: Myths Vs Science, Vivek P. Chavda, Yangmin Chen, Jayant Dave, Zhe-Sheng Chen, Subhash C. Chauhan, Murali M. Yallapu, Vladimir N. Uversky, Rajashri Bezbaruah, Sandip Patel, Vasso Apostolopoulos

School of Medicine Publications and Presentations

Introduction: Several vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed since the inception of the coronavirus disease 2019 (COVID-19) in December 2019, at unprecedented speed. However, these rapidly developed vaccines raised many questions related to the efficacy and safety of vaccines in different communities across the globe. Various hypotheses regarding COVID-19 and its vaccines were generated, and many of them have also been answered with scientific evidence. Still, there are many myths/misinformation related to COVID-19 and its vaccines, which create hesitancy for COVID-19 vaccination, and must be addressed critically to achieve success in the battle against …

Statistical Analysis Methods Applied To Early Outpatient Covid-19 Treatment Case Series Data, Eleftherios Gkioulekas, Peter A. Mccullough, Vladimir Zelenko

School of Mathematical and Statistical Sciences Faculty Publications and Presentations

When confronted with a public health emergency, significant innovative treatment protocols can sometimes be discovered by medical doctors at the front lines based on repurposed medications. We propose a statistical framework for analyzing the case series of patients treated with such new protocols, that enables a comparison with our prior knowledge of expected outcomes, in the absence of treatment. The goal of the proposed methodology is not to provide a precise measurement of treatment efficacy, but to establish the existence of treatment efficacy, in order to facilitate the binary decision of whether the treatment protocol should be adopted on an …

Breakthrough Medicines During The Covid-19 Pandemic Era, Eswara Naga Hanuma Kumar Ghali, Vijian Dhevan, Shravan K. Narmala, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu

School of Medicine Publications and Presentations

No abstract provided.

Covid-19 And Chronic Diabetes: The Perfect Storm For Reactivation Tuberculosis?: A Case Series, Genesis P. Aguillón-Durán, Ericka Prieto-Martinez Dr, Doris Ayala, Juan García Jr., John M. Thomas Iii, Juan Ignacio García, Brandon Michael Henry, Jordi B. Torrelles, Joanne Turner, Eder Ledezma-Campos, Blanca I. Restrepo

School of Medicine Publications and Presentations

Background

The coronavirus disease 2019 pandemic is predicted to have a net negative effect on tuberculosis control, with an estimated excess of 6.3 million tuberculosis cases and 1.4 million deaths by 2025. Programmatic issues such as the lockdown of tuberculosis services affect all patients, while biosocial factors have a differential impact on an individual’s risk for tuberculosis or adverse tuberculosis outcomes.

Case presentation

We report three Hispanic cases of incident tuberculosis (two males, 43 and 44 years old; one female, 49 years old) after resolution of coronavirus disease episodes. Coincidentally, all cases shared a common risk factor: a chronic history …

Implications Of Helminth Immunomodulation On Covid-19 Co-Infections, Nathalie Chacon, Leonor Chacin-Bonilla, Italo M. Cesar

School of Medicine Publications and Presentations

Coronavirus disease 2019 (COVID-19) and helminths infections can be in a synergistic epidemic in developing and suburban areas of industrialized countries. The coinfected hosts will derive a parasite-specific Th2 innate and adaptive immune response with CD4+ T cells, eosinophils, interleukin-4, interleukin-5, and interleukin-10. In the early stages of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, virus-specific Th1 cytotoxic CD8+ T cell, interleukin-6, interferon-γ, and interleukin-27 by lung are keys in controlling viral replication in the lung epithelial cells and limiting the pathology to other organs, like the intestine. CD4+ and CD8+ T cells are associated with protective immunity …

Emerging Issues In Covid-19 Vaccination In Tropical Areas: Impact Of The Immune Response Against Helminths In Endemic Areas, Leonor Chacin-Bonilla, Nathalie Chacón-Fonseca, Alfonso J. Rodriguez-Morales

School of Medicine Publications and Presentations

The Coronavirus Disease 2019 (COVID-19) pandemic has affected over 165 million people and caused the death of 3.4 million worldwide (up to May 20, 2021) (https://coronavirus.jhu.edu/map.html), becoming a serious problem of global public health and the worst epidemic in the last century, after the pandemic 1918 influenza. Researchers worldwide are trying to find valuable drugs against the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Some of them focused as antivirals, others targeted in other ways (e.g. immunomodulation) to relieve the symptoms of the infected patients and help lower the death toll throughout the world. Unfortunately, there is a lack of …

Sars-Cov-2: Potencial Transmisión Feco-Oral E Implicaciones En La Propagación Y Gravedad Del Covid-19 En Venezuela. Mini-Revisión. [Sars-Cov-2: Potential Feco-Oral Transmission And Implications On The Spread And Severity Of Covid-19 In Venezuela. Mini-Review.], Leonor Chacin-Bonilla, Nathalie Chacon

School of Medicine Publications and Presentations

The recognized human-to-human transmission of SARS-CoV-2 is through respiratory droplets and contact with contaminated surfaces. However, the high transmissibility of the virus and the pattern of symptoms of COVID-19 suggest the likelihood of other forms of spread. Increasing evidence suggests that SARS‐CoV‐2 could be transmitted by the feco‐oral route. SARS-CoV-2 is known to infect gastrointestinal epithelial cells and a significant number of infected people have gastrointestinal symptoms. Viable viruses, viral RNA, and prolonged shedding of viral RNA have been detected in the feces of COVID-19 patients. The virus has been found in sewage and surface waters of several countries. The …

Part I. Sars-Cov-2 Triggered 'Panic' Attack In Severe Covid-19, Elliot M. Frohman, Nicole R. Villemarette-Pittman, Esther Melamed, Roberto A. Cruz, Reid Longmuir, Thomas C. Varkey, Lawrence Steinman, Scott S. Zamvil, Teresa C. Frohman

School of Medicine Publications and Presentations

The coronavirus disease 2019 (COVID-19) pandemic has produced a world-wide collapse of social and economic infrastructure, as well as constrained our freedom of movement. This respiratory tract infection is nefarious in how it targets the most distal and highly vulnerable aspect of the human bronchopulmonary tree, specifically, the delicate yet irreplaceable alveoli that are responsible for the loading of oxygen upon red cell hemoglobin for use by all of the body's tissues.

In most symptomatic individuals, the disease is a mild immune-mediated syndrome, with limited damage to the lung tissues. About 20% of those affected experience a disease course characterized …

Part Ii. High-Dose Methotrexate With Leucovorin Rescue For Severe Covid-19: An Immune Stabilization Strategy For Sars-Cov-2 Induced 'Panic' Attack, Elliot M. Frohman, Nicole R. Villemarette-Pittman, Roberto A. Cruz, Reid Longmuir, Vernon Rowe, Elizabeth S. Rowe, Thomas C. Varkey, Lawrence Steinman, Scott S. Zamvil, Teresa C. Frohman

School of Medicine Publications and Presentations

Here, in Part II of a duology on the characterization and potential treatment for COVID-19, we characterize the application of an innovative treatment regimen for the prevention of the transition from mild to severe COVID-19, as well as detail an intensive immunotherapy intervention hypothesis. We propose as a putative randomized controlled trial that high-dose methotrexate with leucovorin (HDMTX-LR) rescue can abolish 'PANIC', thereby 'left-shifting' severe COVID-19 patients to the group majority of those infected with SARS-CoV-2, who are designated as having mild, even asymptomatic, disease. HDMTX-LR is endowed with broadly pleiotropic properties and is a repurposed, generic, inexpensive, and widely …